Lantheus Holdings, Inc. → Perspective Therapeutics, Inc. CATX

Stake: 7.70% Shares: 8,739,011 CUSIP: 46489V302 Class: Common Stock, $0.001 par value

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

5 filings by this filer

4 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 5.52

16,570,625 shares short · -27.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $864K

Point72 Asset Mgmt

Other 13D/G Filings on Perspective Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-09-04	SCHEDULE 13D/A	Lantheus Holdings, Inc.	10.00%	11,440,513	view →
2026-07-20	SCHEDULE 13G	MILLENNIUM MANAGEMENT LLC	—	—	view →
2026-06-30	SCHEDULE 13G	MILLENNIUM MANAGEMENT LLC	—	—	view →

Other Filings by Lantheus Holdings, Inc.

Filed	Form	Issuer	Stake	Shares
2026-09-04	SCHEDULE 13D	Radiopharm Theranostics Limited	20.90%	792,958,513	view →
2026-09-04	SCHEDULE 13D/A	Perspective Therapeutics, Inc.	10.00%	11,440,513	view →
2026-09-04	SCHEDULE 13G	Radiopharm Theranostics Limited	—	—	view →
2020-06-23	SC	PROGENICS PHARMACEUTICALS INC	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →